An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation

Next Previous
Trial Profile

An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms STRATA
  • Sponsors Biogen

    • Most Recent Events

    • 01 Nov 2017 Results of pooled retrospective analysis assessing natalizumab-associated progressive multifocal leukoencephalopathy from four studies (STRATIFY-2, STRATA, TOP, and TYGRIS) published in the Lancet Neurology.
    • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 25 Apr 2015 Results of sub-study presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top